Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Helix Biopharma Corp. (HBPCF) had Return on Tangible Equity of 34.81% for the most recently reported fiscal quarter, ending 2025-07-31.
| Income Statement Financials | |
-- |
|
$-0.70M |
|
-- |
|
-- |
|
$0.70M |
|
$-0.70M |
|
$0.00M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
$-0.70M |
|
55.73M |
|
55.73M |
|
$-0.00 |
|
$-0.00 |
|
| Balance Sheet Financials | |
$0.29M |
|
$0.00M |
|
$13.19M |
|
$13.48M |
|
$2.31M |
|
-- |
|
-- |
|
$2.31M |
|
$11.17M |
|
$-2.01M |
|
$11.17M |
|
74.16M |
|
| Cash Flow Statement Financials | |
$-2.75M |
|
$0.01M |
|
$2.01M |
|
$0.78M |
|
$0.05M |
|
$-0.73M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.13 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.26% |
|
|
Return on Tangible Equity |
34.81% |
-5.19% |
|
-6.26% |
|
$0.15 |
|
$-0.05 |
|
$-0.05 |
|